Evidence map›Paper›PMID 30146423›Full record

ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2018

Risk of ESRD and Mortality in Kidney and Bladder Stone Formers.

Tsering Dhondup, Wonngarm Kittanamongkolchai, Lisa E Vaughan, Ramila A Mehta, Jasdeep K Chhina, Felicity T Enders, LaTonya J Hickson, John C Lieske, Andrew D Rule

Abstract read
In one paragraph

Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 7 pooled it
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 7 syntheses or guidelines pooled it, 144 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Tsering DhondupDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
Wonngarm KittanamongkolchaiDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
Lisa E VaughanDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
Ramila A MehtaDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
Jasdeep K ChhinaDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
Felicity T EndersDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
LaTonya J HicksonDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
John C LieskeDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
Andrew D RuleDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN. Electronic address: rule.andrew@mayo.edu.
Mayo Clinic · US

Funding

Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
VISUALIZATION AND PATHOPHYSIOLOGY OF RENAL STONE PRECURSOR LESIONSU54DK100227 · NIDDK · MAYO CLINIC ROCHESTER · PI LIESKE, JOHN C · 2013 to 2017
$6.3M
Mayo Clinic Urology O'Brien Research CenterP50DK083007 · NIDDK · MAYO CLINIC ROCHESTER · PI LIESKE, JOHN C · 2008 to 2012
$5.3M
Mesenchymal stem cell senescence in diabetic nephropathy (K23 COVID Admin Supplement)K23DK109134 · NIDDK · MAYO CLINIC ROCHESTER · PI HICKSON, LATONYA J · 2016 to 2021
$1.0M
Nephrolithiasis and Chronic Kidney DiseaseR21DK077321 · NIDDK · MAYO CLINIC ROCHESTER · PI LIESKE, JOHN C · 2006 to 2007
$392k
NIA NIH HHS R01 AG034676NIDDK NIH HHS K23 DK109134NIDDK NIH HHS P50 DK083007NIDDK NIH HHS R21 DK077321NIDDK NIH HHS U54 DK100227
6 · The paper itself

Abstract

RATIONALE &

objectivesKidney stones have been associated with increased risk for end-stage renal disease (ESRD). However, it is unclear whether there is also an increased risk for mortality and if these risks are uniform across clinically distinct categories of stone formers. STUDY

designHistorical matched-cohort study. SETTING &

participantsStone formers in Olmsted County, MN, between 1984 and 2012 identified using International Classification of Diseases, Ninth Revision codes. Age- and sex-matched individuals who had no codes for stones were the comparison group. PREDICTOR: Stone formers were placed into 5 mutually exclusive categories after review of medical charts: incident symptomatic kidney, recurrent symptomatic kidney, asymptomatic kidney, bladder only, and miscoded (no stone). OUTCOMES: ESRD, mortality, cardiovascular mortality, and cancer mortality. ANALYTICAL APPROACH: Cox proportional hazards models with adjustment for baseline comorbid conditions.

resultsOverall, 65 of 6,984 (0.93%) stone formers and 102 of 28,044 (0.36%) non-stone formers developed ESRD over a mean follow-up of 12.0 years. After adjusting for baseline hypertension, diabetes mellitus, dyslipidemia, gout, obesity, and chronic kidney disease, risk for ESRD was higher in recurrent symptomatic kidney (HR, 2.34; 95% CI, 1.08-5.07), asymptomatic kidney (HR, 3.94; 95% CI, 1.65-9.43), and miscoded (HR, 6.18; 95% CI, 2.25-16.93) stone formers, but not in incident symptomatic kidney or bladder stone formers. The adjusted risk for all-cause mortality was higher in asymptomatic kidney (HR, 1.40; 95% CI, 1.18-1.67) and bladder (HR, 1.37; 95% CI, 1.12-1.69) stone formers. Chart review of asymptomatic and miscoded stone formers suggested increased risk for adverse outcomes related to diagnoses including urinary tract infection, cancer, and musculoskeletal or gastrointestinal pain.

conclusionsThe higher risk for ESRD in recurrent symptomatic compared with incident symptomatic kidney stone formers suggests that stone events are associated with kidney injury. The clinical indication for imaging in asymptomatic stone formers, the correct diagnosis in miscoded stone formers, and the cause of a bladder outlet obstruction in bladder stone formers may explain the higher risk for ESRD or death in these groups.

Indexed as

Cause of DeathAge FactorsCase-Control StudiesComorbidityFemaleHumansKaplan-Meier EstimateKidney CalculiKidney Failure, ChronicMaleProportional Hazards ModelsRecurrenceRetrospective StudiesRisk AssessmentSex FactorsSurvival Analysisall-cause mortalitybladder stonescancer mortalitycardiovascular mortalitychronic kidney disease (CKD)end-stage renal disease (ESRD)kidney disease risk factorKidney stonesnephrolithiasisrecurrent stone formation

Identifiers

PMID30146423
PMCPMC6252145
OpenAlexW2888587869

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.